Neurologist · Clinical researcher · Healthcare executive
Dr. Rany Aburashed, DO
Founder and CEO of Neurogen Biomarking and Corporate Chief Medical Officer of Insight. Nearly two decades in neurology, multiple sclerosis research and hospital leadership, now focused on finding Alzheimer's risk earlier.
At-home Alzheimer's risk assessment with neurologist review.
Also Corporate Chair of Specialty Services and Neurosciences.
Chicago, Illinois.
About
A neurologist who builds the systems around the patient
Dr. Rany Aburashed is an American neurologist, clinical researcher and healthcare executive. His career spans nearly two decades of patient care, clinical trials and institutional leadership, with a focus on multiple sclerosis, neuroimmunology and the biomarkers that show what is happening inside the nervous system before symptoms make it obvious.
He is the Founder and Chief Executive Officer of Neurogen Biomarking, which he started in 2024 to close the gap between memory concerns and an Alzheimer's diagnosis. At Insight, he serves as Corporate Chief Medical Officer, Corporate Chair of Specialty Services and Neurosciences, and President of Insight Chicago Medical Group.
Before Insight, he founded Memorial Healthcare's Institute for Neurosciences and Multiple Sclerosis in Owosso, Michigan, where he served as Chair of the Department of Neurology, Chair of Specialty Services and Director of the Multiple Sclerosis Comprehensive Center. He has been principal investigator on more than 40 Phase 1–4 clinical trials and is known for applying single-molecule array technology to protein biomarkers in multiple sclerosis.
A graduate of Albion College and the Michigan State University College of Osteopathic Medicine, he completed his neurology residency at Michigan State University and Sparrow Health System, where he was Chief Resident. Albion College named him a 2026 Distinguished Alumni Award recipient.
Career
Clinic, research and leadership
Leadership
-
2024 to present
Founder & Chief Executive Officer
Memory health company pairing at-home blood biomarker testing with digital cognitive assessment and neurologist review.
-
Current
Corporate Chief Medical Officer
- Corporate Chair of Specialty Services and Neurosciences
- President, Insight Chicago Medical Group
-
Previously
Founder, Institute for Neurosciences and Multiple Sclerosis
Memorial Healthcare, Owosso, Michigan- Chair, Department of Neurology
- Chair of Specialty Services
- Director, Multiple Sclerosis Comprehensive Center
- Member, Memorial Healthcare Board of Trustees
Education & training
-
2017
Clinical Neuroimmunology Fellowship
Memorial MS Center -
2007 to 2010
Neurology Residency
Michigan State University / Sparrow Health SystemChief Resident, Department of Neurology, 2009 to 2010.
-
2006 to 2007
Transitional Internship
Sparrow Hospital, Lansing, MichiganDepartment of Internal Medicine.
-
2002 to 2006
Doctor of Osteopathic Medicine
Michigan State University College of Osteopathic MedicineRecipient of the Michigan Medical Grant.
-
1998 to 2002
Bachelor's degree in Psychology, with honors
Albion CollegeAdditional study in world religion.
Neurogen Biomarking
Knowing Alzheimer's risk before the symptoms decide
Dr. Aburashed founded Neurogen Biomarking in 2024 after years of seeing patients and families reach a diagnosis late. The company's mission is to enable early detection of Alzheimer's risk with at-home testing and access to neurologists, so care can start while there is still time to act.
- 1An at-home blood test measures Alzheimer's-related biomarkers, including p-tau217.
- 2A digital cognitive assessment from Linus Health adds a measure of memory and thinking.
- 3A board-certified neurologist reviews the results with the patient by telehealth.
Milestones
-
Linus Health collaboration
Digital cognitive assessments integrated into Neurogen's testing pathway.
Business Wire -
Global agreement with Quanterix
Quanterix blood biomarker assay adopted for Neurogen's patient-initiated blood test.
GlobeNewswire -
NeuroX partnership
Virtual neurology through NeuroX, a subsidiary of American TelePhysicians.
HIT Consultant -
Data at AAIC 2025
Neurogen research on its virtual care model presented at the Alzheimer's Association International Conference.
HIT Consultant -
Tasso partnership
Needle-free Tasso blood collection brought to the at-home testing platform.
Business Wire -
Capillary p-tau217 study published
Clinical performance of fingertip p-tau217 for remote triage, in Alzheimer's & Dementia. Dr. Aburashed is senior author.
PubMed
Research
From multiple sclerosis to Alzheimer's biomarkers
Dr. Aburashed has served as principal investigator on more than 40 Phase 1–4 clinical trials, most in multiple sclerosis and neuroimmunology, covering disease-modifying therapies, treatment response and long-term outcomes. His research centers on precision disease management using neurofilament light chain and protein biomarker profiles, measured with single-molecule array technology. His work has appeared in Neurology: Neuroimmunology & Neuroinflammation, Multiple Sclerosis and Related Disorders and Alzheimer's & Dementia, and has been presented at ECTRIMS.
- Multiple sclerosis
- Neuroimmunology
- Neurofilament light chain
- Blood-based Alzheimer's biomarkers
- Precision disease management
- Neurodegenerative disease
- Clinical trials
Selected publications
-
Capillary brain-derived p-tau217 for remote triaging of Alzheimer's disease pathology: Clinical performance in a CLIA/CAP-certified laboratorySenior author
Alzheimer's & Dementia, 2026 · Thijssen EH, Eghzawi A, et al., Aburashed R · PubMed
-
Foreign Language Syndrome: Neurological and Psychiatric Aspects
Neurology International, 2025 · Eghzawi A, Madha A, Aburashed R · PubMed
-
Neurofilament Light Chain and Multiple Sclerosis: Building a Neurofoundational Model of Biomarkers and DiagnosisFirst author
Neurology International, 2025 · Aburashed R, Eghzawi A, Long D, Pace R, Madha A, Cote J · PubMed
-
Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab
Multiple Sclerosis and Related Disorders, 2023 · Bar-Or A, Aburashed R, et al. · PubMed
-
Interferon-β Decreases the Hypermetabolic State of Red Blood Cells from Patients with Multiple Sclerosis
ACS Chemical Neuroscience, 2022 · Jacobs M, et al., Aburashed R, Spence D · PubMed
-
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
Neurology and Therapy, 2021 · Hunter SF, Aburashed RA, et al. · PubMed
-
Malignant cerebral edema secondary to hyperammonemia in setting of acquired carnitine deficiency
Neurology: Clinical Practice, 2020 · Long D, Derani T, Gheith T, Aburashed R, Saeed A · PubMed
-
CNS-disseminated Angiostrongylus cantonensis mimicking atypical demyelinating diseaseSenior author
Neurology: Neuroimmunology & Neuroinflammation, 2019 · Long D, Green K, Derani T, Decker N, Pace RJ, Aburashed R · PubMed
-
Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment
Journal of Investigative Medicine High Impact Case Reports, 2017 · Himedan M, et al., Aburashed R, Mao-Draayer Y · PubMed
-
Cerebral venous and sinus thrombosis associated with subcutaneous immunoglobulin injection and oral contraceptive use
Neurological Sciences, 2012 · Min J, Bhatt A, Aburashed R, Burton S · PubMed
-
Hereditary neuropathy with liability to pressure palsies and amyotrophic lateral sclerosis
Neurological Sciences, 2009 · Bhatt A, Farooq MU, Aburashed R, et al. · PubMed
-
Therapeutic role of zonisamide in neuropsychiatric disorders
Mini-Reviews in Medicinal Chemistry, 2008 · Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY · PubMed
Press, podcasts & talks
In the media
Earlier coverage includes CNN, Nasdaq, Yahoo News and USA Today. For media requests, see contact.
Recognition & service
Awards and honors
- 2026Distinguished Alumni AwardAlbion College
- 2024Notable Leaders in Health CareCrain's Chicago Business
- 2018Physician Leadership RecognitionYoga Moves MS
- 201840 Under 40, nomineeCrain's Detroit Business
- 2009Resident of the YearDepartment of Neurology, Michigan State University
- 2006Richard L. Alper Memorial Award
- 2005Student of the YearMichigan State University
He has also received Patients' Choice and Compassionate Doctor awards.
Boards, advisory work and teaching
Dr. Aburashed has served on the Memorial Healthcare Board of Trustees and the National Multiple Sclerosis Society Board of Trustees. His advisory and educational work includes engagements with Biogen, Genentech, Sanofi, Novartis and EMD Serono. He has trained medical students, neurology residents and fellows through bedside teaching, multiple sclerosis electives and lectures.
Quick answers
Frequently asked
Who is Dr. Rany Aburashed?
Rany Aburashed, DO is an American neurologist, clinical researcher and healthcare executive. He is the Founder and CEO of Neurogen Biomarking and the Corporate Chief Medical Officer of Insight, where he is also Corporate Chair of Specialty Services and Neurosciences and President of Insight Chicago Medical Group.
What is Neurogen Biomarking?
Neurogen Biomarking is a memory health company Dr. Aburashed founded in 2024. It combines an at-home blood test for Alzheimer's-related biomarkers with a digital cognitive assessment and a review of results by a board-certified neurologist.
What is the Neurofoundational Model?
A conceptual teaching model from a 2025 Neurology International paper led by Dr. Aburashed. It uses the analogy of a house and its foundation to explain how changes in neurofilament light chain relate to nerve-cell injury in multiple sclerosis. The authors describe it as an educational tool, not a diagnostic test.
Where did Dr. Aburashed train?
He earned a bachelor's degree in psychology with honors from Albion College in 2002 and his Doctor of Osteopathic Medicine from the Michigan State University College of Osteopathic Medicine in 2006. He completed a transitional internship at Sparrow Hospital, a neurology residency at Michigan State University and Sparrow Health System, where he was Chief Resident, and a clinical neuroimmunology fellowship.
What is his clinical specialty?
Neurology, with subspecialty focus in neuroimmunology and multiple sclerosis. He is board certified in neurology by the American Board of Psychiatry and Neurology.
Contact
Media, speaking and partnerships
For interviews, speaking invitations and partnership inquiries, contact the Neurogen Biomarking media team or connect with Dr. Aburashed on LinkedIn.